Skip to main content
ArticleOPEN ACCESS

Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients

American Journal of Hematology
DOI: 10.1002/ajh.23219
36Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A multicenter randomized open-label long-term sequential deferiprone-deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].

Cite

CITATION STYLE

APA

Maggio, A., Vitrano, A., Lucania, G., Capra, M., Cuccia, L., Gagliardotto, F., … Rigano, P. (2012, July). Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients. American Journal of Hematology. https://doi.org/10.1002/ajh.23219

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free